用循证观点看待肝硬化门静脉血栓诊治中的争议

摘要/Abstract

摘要： 门静脉血栓(PVT)是肝硬化患者常见的并发症,但肝硬化PVT分类方法及危险因素尚不明确,对肝硬化预后的临床影响存在争议。目前肝硬化PVT常用治疗方法包括抗凝、介入和溶栓等,但这些方法的的安全性和应用指征尚缺乏高级别的临床医学证据。因此,本文针对PVT诊断和治疗的争议性观点进行探讨,提出伴有食管胃静脉曲张的肝硬化PVT的处理。

关键词: 门静脉血栓, 肝硬化, 危险因素, 抗凝治疗, 静脉曲张

车莹, 黄晓铨, 陈世耀. 用循证观点看待肝硬化门静脉血栓诊治中的争议[J]. 肝脏, 2022, 27(3): 261-263.

[1] Senzolo M, Garcia-Tsao G, García-Pagán J. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol,2021.
[2] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年,上海). 中华肝脏病杂志,2020,28:999-1007.
[3] 黄晓铨, 倪礼爰, 姜思雨,等. 门静脉血栓影响内镜治疗预防乙型肝炎肝硬化食管胃静脉曲张破裂再出血的疗效. 中华肝脏病杂志,2020,28:747-752.
[4] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology. 2021.
[5] Maruyama H, Okugawa H, Takahashi M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol,2013,108:568-574.
[6] Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol,2021.
[7] Xu X, Guo X, Stefano VD, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int,2019,13:468-481.
[8] Nery F, Correia S, Macedo C, et al. Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. Aliment Pharmacol Ther. 2019,49:582-588.
[9] La Mura V, Tripodi A, Tosetti G, et al. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. Liver Int,2016,36:1322-1330.
[10] Huang X, Fan X, Zhang R, et al. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices. European Journal of Gastroenterology & Hepatology, 2020,32.
[11] Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol,2017,67:950-956.
[12] Zhang Y, Xu BY, Wang XB, et al. Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation. Clin Gastroenterol Hepatol,2020,18:2564-2572.e1.
[13] Stine JG, Shah NL, Argo CK, et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl,2015,21 21:1016-1021.
[14] Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology,2012,265:124-132.
[15] Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology,2015,61:660-667.
[16] Pettinari, Vukotic, Stefanescu, et al. Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Am J Gastroenterol,2019,114:258-266.
[17] Dong S, Qi H, Li Y. A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat? Hepatol Int, 2021, 15:1356-1375.
[18] Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019,49:20-30.
[19] Lv Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut,2018,67:2156-2168.

用循证观点看待肝硬化门静脉血栓诊治中的争议

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐强, 方玮, 孙高亚, 吴炎. 肝硬化心肌病诊断与治疗研究进展[J]. 肝脏, 2022, 27(3): 267-270.
[2]	李锦秀, 沈镇扬, 蔡晓波, 陆伦根. 慢性肝病肝纤维化人群早期筛查的临床研究进展[J]. 肝脏, 2022, 27(3): 271-272.
[3]	任海霞, 闫华楠, 牛淑利, 郭永泽, 李博, 张宏伟, 安凯. 肝硬化患者口腔和肠道菌群的变化及其相关性[J]. 肝脏, 2022, 27(3): 330-333.
[4]	张丽丽, 胡建华, 靳华, 徐辉. 终末期原发性胆汁性肝硬化23例临床特点分析[J]. 肝脏, 2022, 27(3): 337-340.
[5]	刘宁, 周莹群. 胆汁酸对肝硬化疾病进展及治疗的意义[J]. 肝脏, 2022, 27(3): 376-379.
[6]	任天羿, 范建高. 2021慢性肝病临床研究重大进展回顾[J]. 肝脏, 2022, 27(2): 133-136.
[7]	夏睿琦, 曾晓清, 陈世耀. 非选择性β受体阻滞剂在代偿性肝硬化患者中的新应用[J]. 肝脏, 2022, 27(2): 141-144.
[8]	陈颖, 方青青, 陈炜, 张君佩, 沈丹杰, 李煜, 简佑容, 李锋, 王剑, 陈世耀. 血小板计数与脾脏直径比值对乙型肝炎肝硬化高危食管胃静脉曲张的预测价值[J]. 肝脏, 2022, 27(2): 164-168.
[9]	甄勇, 王兵济, 杜华劲, 高学健, 王仔平, 宣佶, 张尊庶, 王传泰, 耿家宝. 抗凝治疗在肝硬化患者脾切除术后减少PVT的疗效及安全性研究[J]. 肝脏, 2022, 27(2): 169-173.
[10]	王雪伟, 黄晓云, 庞长绪, 乔超峰, 李彩霞. 超声观察不同肝功能分级肝硬化患者左室峰值应变离散度的价值[J]. 肝脏, 2022, 27(2): 174-177.
[11]	秦旭, 侯志云, 张松, 马丽, 朝浩鹏. S基因突变对慢性乙型肝炎肝硬化患者血清AFP、PTX3表达及预后的影响[J]. 肝脏, 2022, 27(2): 178-181.
[12]	冯权烨, 耿承军, 殷慧康. T2WI序列图像TA在肝硬化背景下结节及小肝癌鉴别诊断中的应用[J]. 肝脏, 2022, 27(2): 193-195.
[13]	杨静仪, 勾熙, 毛小荣, 李俊峰. 肌肉减少症对终末期肝病临床结局和预后影响的研究进展[J]. 肝脏, 2022, 27(2): 245-247.
[14]	李莉, 孙双双, 金银鹏, 傅青春. 特发性非硬化性门静脉高压症1例报道及文献复习 [J]. 肝脏, 2022, 27(2): 255-256.
[15]	冯丽娟, 贾继东. 关于肝硬化并发症诊治的共识与争议[J]. 肝脏, 2022, 27(1): 4-7.